Z08 Insurance Policy Changes

ICD-10 Z08 is officially defined as "Encounter for follow-up examination after completed treatment for malignant neoplasm." code Z08 is referenced in 5 tracked payer policy changes from Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z08 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Aug 20, 2026High impact
Bone Densitometry/Bone Density Studies 6.01.05
Effective August 20, 2026, VFA with DEXA and TBS was removed from the list of investigational screening procedures, and DEXA can be completed with or without VFA or TBS. BMD testing is considered medically necessary when one of the listed methods is used, including DEXA, and one of the listed indications is met. Follow-up BMD testing is considered medically appropriate every two years, when at least 23 months have passed since the month of the last test, and testing every three years is recommended after starting bisphosphonate therapy.
Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Prostate Specific Antigen (PSA)
Effective 10/01/2026, the code reference adds ICD-10 diagnosis codes QA1.790 (familial cancer syndrome with pathogenic BRCA1 mutation), QA1.791 (familial cancer syndrome with pathogenic BRCA2 mutation), and QA1.792 (Li Fraumeni syndrome), which are listed among the medically necessary codes for prostate specific antigen testing. Prostate specific antigen may be considered medically necessary to differentiate benign from malignant prostate disease in men with listed lower urinary tract symptoms or abnormal studies, to follow prostate cancer after diagnosis, and to screen for malignant prostate disease with documented shared decision making. PSA is considered not medically necessary for all other indications.
Healthfirst · Identified Oct 2, 2026Medium impact
National Breast Cancer Awareness Month (Oct 2026): Documentation and Coding Resources for Your Practice
Healthfirst has released updated documentation and coding guidance for breast cancer diagnosis and treatment to ensure accurate ICD-10-CM code selection. The policy clarifies how to code malignant neoplasms, metastatic disease, adjuvant therapy (curative vs. prophylactic), and follow-up care, with critical distinctions between active treatment and post-treatment status that directly impact claim coding accuracy.
Healthfirst · Identified Sep 2, 2026Medium impact
Prostate Cancer Awareness Month (Sept 2026): Documentation and Coding Resources for Your Practice
Healthfirst has released updated documentation and coding guidance for prostate cancer diagnosis coding to improve accuracy and specificity. The resource provides ICD-10-CM code selection rules, documentation requirements, and examples for active treatment, surveillance, and metastatic cases to ensure proper claim submission to Healthfirst.
Aetna · Identified Aug 19, 2026Medium impact
Magnetic Resonance Cholangiopancreatography (CPB 0384, reviewed 2026-06-25)
Aetna's clinical policy bulletin covers magnetic resonance cholangiopancreatography (MRCP) and lists the indications it considers medically necessary. These include preoperative evaluation of the common bile duct before laparoscopic cholecystectomy in persons with elevated transaminases or common bile duct dilatation on abdominal ultrasound or CT, and members who only need diagnosis of suspected pancreaticobiliary pathology without therapeutic intervention. The bulletin also lists a documented allergy to iodine-based contrast materials or a general history of atopy, altered biliary tract anatomy that precludes ERCP, and unsuccessful ERCP that requires further evaluation. Other listed indications include infants or young children, or adults who are debilitated or uncooperative, in whom ERCP is unsafe or cannot be performed, biliary obstruction in orthotopic liver transplant recipients, a disrupted or disconnected pancreatic duct in acute pancreatitis, diagnosing and monitoring primary sclerosing cholangitis, diagnosing, staging and surveilling pancreatic cancer, and postsurgical surveillance of intraductal papillary mucinous neoplasm of the pancreas. Aetna considers MRCP for all other indications experimental, investigational or unproven. Aetna also considers quantitative MRCP experimental, investigational or unproven for evaluation of bile duct, gallbladder, liver, pancreas and pancreatic duct diseases.

Watch Z08

Get one email when a payer policy names Z08, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z08?

There are 5 tracked policy changes affecting code Z08, including updates from Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Healthfirst. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z08?

Payers that have issued tracked updates for code Z08 include: Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Healthfirst, Aetna.

How do I get notified when code Z08 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z08. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z08?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Bone Densitometry/Bone Density Studies 6.01.05

Prostate Specific Antigen (PSA)

National Breast Cancer Awareness Month (Oct 2026): Documentation and Coding Resources for Your Practice

Prostate Cancer Awareness Month (Sept 2026): Documentation and Coding Resources for Your Practice

Magnetic Resonance Cholangiopancreatography (CPB 0384, reviewed 2026-06-25)

What insurance policy changes affect code Z08?

Which payers have updated policy for code Z08?

How do I get notified when code Z08 policy changes?

Why do payers change policies for code Z08?